Skip to content

Checked

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

NCT01311258 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Observational
Planned enrollment
400
Participants, all sites
U.S. sites
1
In 1 state

Study details

Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Sponsor
University of Rochester (University, hospital or other organization)
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Start
August 2007
Primary completion (expected)
August 2030
Last updated by sponsor
09/17/2025

Full eligibility rules, contacts and site names: NCT01311258 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • New York: Rochester

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 09/17/2025